Timothy R. Morgan
Professor, Medicine
School of Medicine
School of Medicine
M.D., Emory University
University of California, Irvine
VAMCLB
101 The City Drive
Mail Code: 8900
Orange, CA 92668
VAMCLB
101 The City Drive
Mail Code: 8900
Orange, CA 92668
Research Interests
Cirrhosis, Viral hepatitis, Alcoholic Liver Disease
Academic Distinctions
2013 Long Beach VA Inpatient Attending Teaching Award
Presented by the UCI Internal Medicine Residents
2013 National Cancer Institute Clinician Award
2012 Special Award from the University of California for being an Outstanding Clinical
Researcher (leading enroller) for Clinical Trials funded by the Division of Cancer
Prevention, National Cancer Institute
2007 Special Contribution Award, Public Health Strategic Healthcare Group
VA Central Office, Washington, DC
2007 Certificate of Appreciation, VA Long Beach Healthcare System
2007 Performance Improvement Award for “Improving the Hepatitis C Clinical Case Registry”
2006 Outstanding Teacher, UCI and VA Gastroenterology Fellows
2006 Certificate of Appreciation, VA National Liver Transplant Program,
VA Central Office, Washington, DC
2006 Special Contribution Award, Public Health Strategic Healthcare Group
VA Central Office, Washington, DC
2006 Performance Improvement Award for “Curing the Liver Clinic”
2005 Special Contribution Award, Public Health Strategic Healthcare Group
VA Central Office, Washington, DC
2001 Outstanding Teacher, UCI &VA Gastroenterology Fellows
1994 Outstanding Teacher, UCI &VA Gastroenterology Fellows
1974 Phi Beta Kappa, Northwestern University
Presented by the UCI Internal Medicine Residents
2013 National Cancer Institute Clinician Award
2012 Special Award from the University of California for being an Outstanding Clinical
Researcher (leading enroller) for Clinical Trials funded by the Division of Cancer
Prevention, National Cancer Institute
2007 Special Contribution Award, Public Health Strategic Healthcare Group
VA Central Office, Washington, DC
2007 Certificate of Appreciation, VA Long Beach Healthcare System
2007 Performance Improvement Award for “Improving the Hepatitis C Clinical Case Registry”
2006 Outstanding Teacher, UCI and VA Gastroenterology Fellows
2006 Certificate of Appreciation, VA National Liver Transplant Program,
VA Central Office, Washington, DC
2006 Special Contribution Award, Public Health Strategic Healthcare Group
VA Central Office, Washington, DC
2006 Performance Improvement Award for “Curing the Liver Clinic”
2005 Special Contribution Award, Public Health Strategic Healthcare Group
VA Central Office, Washington, DC
2001 Outstanding Teacher, UCI &VA Gastroenterology Fellows
1994 Outstanding Teacher, UCI &VA Gastroenterology Fellows
1974 Phi Beta Kappa, Northwestern University
Research Abstract
Dr. Morgan’s clinical research interest is treatment of hepatitis C and hepatitis B, as well as alcoholic hepatitis. His laboratory research is in the are of non-alcoholic steatohepatitis
Publications
Manns MP, McHutchison JG, Gordon SC, Rustigi VK, Schiffman M, Reindollar R, Goodman ZD, Koury K, Ling M-H and the International Hepatitis Interventional Therapy Group [TR Morgan, member]. Peginterferon alfa-2b in combination with ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: results of a randomized trial. Lancet 2001 Sept 22;358:958-65.
Morgan K, French SW, Morgan TR. Increased liver damage in cytochrome P450 2E1 transgenic mice fed ethanol. Hepatology 2002;36(1):122-34.
Strader DB, Bacon BR, Lindsay KL, La Brecque DR, Morgan T, Wright EC, Allen J, Khokar MF, Hoofnagle JH, Seeff LB. Use of complementary and alternative medicine among patients with liver disease. American Journal of Gastroenterology 2002;97(9):2391-7.
Morgan TR, Brenner D, Everhart J, French SW, Fried MW, Gretch DR, Koziel MJ, McClain CJ, Peters MG, Weinman SA Lucas D. Hepatitis C and alcohol: Fundamental and translational research directions. Alcoholism Clinical Experimental Research 2003 27:726-31.
Jamal MM, Morgan TR. Hepatitis C and alcohol. Best Practice & Research Clinical Gastroenterology 2003;17:649-662
Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Lin A, Ackrill A, and the PEGASYS International Study Group. Peginterferon alfa-2a (40 KD) plus ribavirin in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Annals Internal Medicine 2004;140:346-355.
Shiffman ML, Di Bisceglie A, Lindsay KL, Morishima C, Wright EC, Everson G, Lok A, Morgan TR, Bonkovsky H, Lee William, Dienstag J, Ghany M, Everhart J, and the HALT-C study group. Peginterferon alfa-2a for retreatment of patients with chronic HCV who have failed prior treatment with interferon or interferon and ribavirin: results from the lead-in phase of the hepatitis C long-term antiviral treatment against cirrhosis (HALT-C) trial. Gastroenterology 2004;126(4):1015-23.
Bini EJ, Brau N, Curie S, Shen H, Anand BS, Hu K-Q, Jeffers L, Ho SB, Johnson D, Schmidt W, King P, Cheung R, Morgan TR, Awad J, Pedrosa M, Chang K-M, Aytaman A, Simon F, Hagedorn K, Moseley R, Ahmad J, Mendenhall C, Waters B, Strader D, Sasaki A, Rossi S, Wright TL. Epidemiology of hepatitis C and eligibility for antiviral therapy in United States veterans. Am J. Gastroenterology 2005;100(8):1772-9
Morgan TR, Weiss DG, Nemchausky B, Schiff ER, Anand B, Simon F, Kidao J, Bennet C, Mendenhall CL, Nelson D, Lieber CS, Pedrosa M, and the CSP 352 study group. Colchicine treatment of alcoholic cirrhosis: a prospective, randomized, placebo-controlled trial of patient survival. Gastroenterology 2005;128:882-890.
Lok AS, Ghany MG, Goodman Z, Wright EC, Everson GT, Sterling RK, Everhart JE, Di Bisceglie A, Lindsay K, Lee W, Bonkovsky H, Morgan TR, Dienstag J, Morishima C, and the HALT-C Trial Group. Predicting cirrhosis in patients with hepatitis C using standard laboratory tests: results of the HALT-C cohort. Hepatology 2005;42(2):282-92.
Mandayam S, Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. Seminars in Liver Disease 2004;24(3):217-32
Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004;127(5, supplement):S87-S96.
Morgan TR. Clinical usefulness of the Glasgow Alcoholic Hepatitis Score. Nature Clinical Practice Gastroenterology & Hepatology 2006;3(1):4-5 (editorial).
Jamal MM, Saadi Z, Morgan TR. Liver disease in alcohol and hepatitis C. Digestive Diseases 2005;23:285-296.
Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B, Feasibility of identifying HCV genotype 1 patients who respond to 24 weeks of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology 2006;43:954-60.
Morishima C, Morgan TR, Everhart JE Wright EC, Naishadham D, Gretch DR, and HALT-C study group. Utility of a transcription mediated amplification assay for detection of hepatitis C virus RNA during combination therapy in the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology 2006;44:360-367
Shiffman ML, Ghany MG, Morgan TR, Wright EC and HALT-C study group. Dose reduction and sustained virologic response: results from the HALT-C study. Gastroenterology 2007;132:103-12
Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Fried MW, Hadziyannis S, Levy D, Wright TL. Impact of ribavirin dose reductions in HCV genotype 1 patients treated with peginterferon alfa-2a plus ribavirin. Clin Gastroentero Hepatol 2007;5(1):124-9
Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, Shafran SD, Baranger K, Lin A, Soman A, Zeuzem S and the ACCELERATE Investigators (TR Morgan, Member). Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Eng J Med 2007;357:124-34.
Hoefs JC, Morgan TR. 72 weeks of treatment for patients with partial EVR? (editorial). Hepatology 2007;46:1671-4
Di Bisceglie A, Shiffman M, Everson G, Lindsay K, Everhart JE, Wright E, Lee W, Lok A, Bonkovsky H, Morgan TR, Ghany M, Morishima C, Snow K, Dienstag J. Prolonged therapy of advanced hepatitis C with low-dose peginterferon: The hepatitis C long-term treatment against cirrhosis (HALT-C) trial. New England Journal of Medicine (in revision)
Morgan K, Uyuni A, Nandgiri G, Mao L, Casteneda L, Kathirvel E, French SW, Morgan TR. Altered expression of transcription factors controlling lipogenesis during fasting and feeding in an animal model of non-alcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology 2008
Morgan TR, Weiss DG, Nemchausky B, Schiff ER, Anand B, Simon F, Kidao J, Bennet C, Mendenhall CL, Nelson D, Lieber CS, Pedrosa M, and the CSP 352 study group. Colchicine treatment of alcoholic cirrhosis: a prospective, randomized, placebo-controlled trial of patient survival. Gastroenterology 2005;128:882-890.
Lok AS, Ghany MG, Goodman Z, Wright EC, Everson GT, Sterling RK, Everhart JE, Di Bisceglie A, Lindsay K, Lee W, Bonkovsky H, Morgan TR, Dienstag J, Morishima C, and the HALT-C Trial Group. Predicting cirrhosis in patients with hepatitis C using standard laboratory tests: results of the HALT-C cohort. Hepatology 2005;42(2):282-92.
Bardag-Gorce F, Wilson L, Nan L, Li J French, BA, Morgan TR, Morgan K, French SW. CYP2E1 inhibition enhances Mallory body formation. Exp Mol Pathol 2005;78(3):207-11.
Morgan TR. Clinical usefulness of the Glasgow Alcoholic Hepatitis Score. Nature Clinical Practice Gastroenterology & Hepatology 2006;3(1):4-5 (editorial). [PMID: 16397604]
Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B, Feasibility of identifying HCV genotype 1 patients who respond to 24 weeks of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology 2006;43:954-60. PMID: 16628671
Chen S, Morgan TR. Natural history of hepatitis C. Int J Med Sci 2006;3(2):47-52. [PMID: 16614742]
Morishima C, Morgan TR, Everhart JE Wright EC, Naishadham D, Gretch DR, and HALT-C study group. HCV RNA detection by TMA during the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) trial. Hepatology 2006;44:360-367. [PMID: 16871570]
Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, Rogers TE, Banner BF, Shiffman ML, Lindsay KL, Lok ASF, Di Bisceglie AM, Ghany MG, Morishima CM, Everhart JE and the HALT-C study group [TR Morgan, member]. Role of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006;131:1440-51. [PMID: 17196293]
Hu Q-K, Currie SL, Shen H, Cheung RC, Ho SB, Bini EJ, McCracken J, Morgan TR, Brau N, Schmidt WN, Jeffers L, Wright TL for the VA HCV001 Study Group. Clinical implications of hepatic steatosis in patients with hepatitis C: a retrospective analysis of a US multicenter study. Digestive Disease and Sciences 2007;52(2):570-8
Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Gretch DR and HALT-C study group. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007;132:103-12. [PMID: 17241864]
Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Fried MW, Hadziyannis S, Levy D, Wright TL. Impact of ribavirin dose reductions in HCV genotype 1 patients treated with peginterferon alfa-2a plus ribavirin. Clin Gastroentero Hepatol 2007;5(1):124-9. [PMID: 17196435]
Bonkovsky, HL, Snow KK, Malet PF, Black-Madruga C, Fontana RJ, Sterling RK, Kulig CC, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG, Gretch DR, and the HALT-C group. Health-related quality of life in chronic hepatitis C patients with advanced fibrosis. J Hepatology 2007;46(3):420-31. [PMID: 17196293]
Lok AS, Everhart JE, Chung RT, Padmanabhan L, Greeson JK, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Morgan TR, Ghany MG, Morishima C and the HALT-C trial group. Hepatic steatosis is associated with fibrosis and impaired antiviral response in non-diabetics with hepatitis C: analysis of data from the HALT-C clinical trial. Clinical Gastroenterol Hepatol 2007;5(2):245-54. [PMID: 17296533]
Everson GT, Martucci MA, Shiffman ML, Sterling R, Morgan TR, Hoefs JC. Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt. Alimentary Pharmacology and Therapeutics 2007;26(3):401-410. [PMID: 17635375]
Hoefs JC, Morgan TR. 72 weeks of treatment for patients with partial EVR? (editorial). Hepatology 2007;46:1671-4. [PMID: 18046713]
Morgan TR, Lambrecht RW, Bonkovsky HL, Chung RT, Naishadham D, Wright EC, O’Brien TR. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: Results from the HALT-C trial. Journal of Hepatology 2008;49(4):548-556. [PMID: 18619701]
Fried MW, Jensen D, Rodriguez-Torres M, Nyberg L, Di Bisceglie AM, Morgan TR, Pockros P, Lin A, Cupelli L, Duff F, Wang K, Nelson D. Improved outcomes in HCV patients with difficult to treat characteristics: randomized study of higher doses of peginterferon alfa-2a and ribavirin. Hepatology 2008;48:1033-1043. [PMID: 18697207]
Morishima C, Morgan TR, Everhart JE, Wright EC, Chung E, Gretch DR and the HALT-C Trial Group. Interpretation of TMA test results from PCR-negative samples obtained during and after treatment of chronic hepatitis C. Hepatology 2008;48:1412-1419.
Di Bisceglie A, Shiffman M, Everson G, Lindsay K, Everhart JE, Wright E, Lee W, Lok A, Bonkovsky H, Morgan TR, Ghany M, Morishima C, Snow K, Dienstag J. Prolonged therapy of advanced hepatitis C with low-dose peginterferon: The hepatitis C long-term treatment against cirrhosis (HALT-C) trial. New England Journal of Medicine 2008;359:2429-41.
Lok AS, Seeff LB, Morgan TR, Di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD, and the HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009;136:138-148.
Rodriguez-Torres M, Govindarajan S, Diago M, Morgan TR, Anand B, Barange K, Suter F, Lin A, Hooper G, Shiffman M. Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alfa-2a plus ribavirin for 16 or 24 weeks. Liver International 2009;29(2):237-41. [PMID: 18710427]
Butura A, Nilsson K, Morgan K, Morgan TR, French SW, Johansson I, Schuppe-Koistinen I, Ingelman-Sundberg M. Impact of CYP2E1 on development of alcoholic liver disease as studied in a transgenic mouse model. J Hepatol 2009;50(3):572-83. [PMID: 19157621]
Everson GT, Shiffman ML, Morgan TR, Hoefs JC, Sterling RK, Wagner DA, DeSanto J, Curto TM, Wright EC and the HALT-C trial group. Hepatic improvement after sustained virologic response as measured by quantitative tests of liver function: Results from the HALT-C trial. Alimentary Pharmacology and Therapeutics 2009;29(5):589-601 [PMID: 19053983].
Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer R, Wright EC, Hutchinson A, Crenshaw A, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, DiBisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT, O’Brien TR. Variants in interferon alpha pathway genes and response to pegylated-interferon and ribavirin for treatment of chronic HCV infection in the HALT-C trial. Hepatology 2009;49(6):1847-58. [PMID: 19434718]
Lucey M, Mathurin P, Morgan TR. Medical Progress Report: Alcoholic Hepatitis. New England Journal of Medicine 2009;360:2758-69. [PMID: 19553649]
Everhart JE, Lok AS, Kim H-Y, Morgan TR, Lindsay KL, Chung RT, Bonkovsky HL, Ghany MG and the HALT-C trial group. Weight related effects on liver disease progression in the Hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 2009;137:549-57.
Kathirvel E, Morgan K, French SW, Morgan TR. Over-expression of liver-specific CYP2E1 impairs hepatic insulin signaling in a transgenic mouse model of non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2009;21:973-983. [PMID: 19307976]
McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis NM, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS and the IDEAL Study Team [T Morgan, member]. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Eng J Med 2009;361:580-93.
Rodriguez-Torres M, Govindarajan S, Diago S, Morgan TR, Anand B, Barange K, Suter F, Lin A, Hooper G, Shiffman M. Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a plus ribavirin for 16 or 24 weeks. Liver International 2009;29(2):237-41 [PIMD: 18710427]
Ge L, Zhang JG, Samathanum CA, Delgado C, Tarbiyat-Boldaji M, Dan Q, Hoa N, Alipanah R, Nguyen TV, Pham JT, Sanchez R, Wepsic HT, Morgan TR, Jadus M. Cytotoxic T cell immunity against the non-immunogenic, murine, hepatocellular carcinoma Hepa1-6 is directed towards the novel alternative form of macrophage colony stimulating factor. Cellular Immunology 2009;259:117-127
Goodman ZD, Stoddard AM, Bonkovsky HL, Fontana RJ, Ghany MG, Morgan TR, Wright EC and the HALT-C trial group. Fibrosis progression in hepatitis C: morphometric analysis of the HALT-C trial. Hepatology 2009;50(6):1738-49 [PIMD: 19824074]
Lok AS, Everhart JE, Chung RT, Kim H-Y, Everson G, Hoefs J, Greenson JK and the HALT-C trial group [TR Morgan, member]. Evolution of hepatic steatosis in patients with advanced hepatitis C in the HALT-C trial and its impact on progression to cirrhosis. Hepatology 2009;49(6):1828-37 [PIMD: 19291787]
Shiffman ML, Morishima C, Lindsay KL, Hoefs JC, Lee WM, Dienstag JL, Wright EC, Naishadham D, and the HALT-C trial group [TR Morgan, member]. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology 2009;137(6):1986-94 [PIMD: 19747918]
Ghany MC, Lok ASF, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, DiBisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL and the HALT-C trial group. Predicting clinical and histological outcomes based on standard laboratory tests: analysis of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial cohort. Gastroenterology 2010;138(1):136-146 [PIMD: 19766643]
Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, DiBisceglie AM, Morgan TR, Kim H-Y and the HALT-C trial group. Des-gamma-carboxy prothrombin and alpha fetoprotein as biomarkers for hepatocellular carcinoma surveillance: results from the HALT-C trial. Gastroenterology 2010;138:493-502 [PIMD:
Kathirvel E, Chen P, Morgan K, French SW, Morgan TR. Oxidative stress and regulation of antioxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver. Journal of Gastroenterology and Hepatology 2010;25:1136-1143.
Snow KK, Bonkovsky HL, Fontana RJ, Kim H-Y, Sterling R, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG and the HALT-C trial group. Changes in quality of life and sexual health are associated with low dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics 2010;31:719-734
Fontana RJ, Sanyal AJ, Ghany MG, Lee WM, Reid AE, Naishadham D, Everson GT, Kahn JA, DiBisceglie AM, Szabo G, Morgan TR, Everhart JE and the HALT-C trial group. Development and progression of esophageal varices in patients with chronic hepatitis C in a prospective multicenter study. Gastroenterology 2010;138:2321.
Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML, Fontana RJ, DiBisceglie AM, Bonkovsky HL, Dienstag JL and the HALT-C Trial group. Complication rate of percutaneous liver biopsy among persons with advanced chronic liver disease in the HALT-C Trial. Clinical Gastroenterology and Hepatology 2010: [PIMD: 20362695]
Morgan TR, Ghany MG, Kim HY, Snow KS, Shiffman ML, DeSanto JL, Lee WM, DiBisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS. Outcomes of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010:52:833-844 [PIMD: 20564351]
Kathirvel E, Morgan K, Nandgiri G, Sandoval BC, Caudill M, Bottiglieri T, French SW, Morgan TR. Betaine improves non-alcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine. Am J Physiol 2010.
Mathurin P, O’Grady J, Carithers RL, Philipps M, Louvet A, Raymond M-J, Neaveau S, Morgan TR, Maddrey WC, Mendenhall CL. Corticosteroids improve short term survival in patients with severe alcoholic hepatitis: individual data analysis of the last five randomized controlled trials. Gut 2010
Morgan K, French SW, Morgan TR. Increased liver damage in cytochrome P450 2E1 transgenic mice fed ethanol. Hepatology 2002;36(1):122-34.
Strader DB, Bacon BR, Lindsay KL, La Brecque DR, Morgan T, Wright EC, Allen J, Khokar MF, Hoofnagle JH, Seeff LB. Use of complementary and alternative medicine among patients with liver disease. American Journal of Gastroenterology 2002;97(9):2391-7.
Morgan TR, Brenner D, Everhart J, French SW, Fried MW, Gretch DR, Koziel MJ, McClain CJ, Peters MG, Weinman SA Lucas D. Hepatitis C and alcohol: Fundamental and translational research directions. Alcoholism Clinical Experimental Research 2003 27:726-31.
Jamal MM, Morgan TR. Hepatitis C and alcohol. Best Practice & Research Clinical Gastroenterology 2003;17:649-662
Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Lin A, Ackrill A, and the PEGASYS International Study Group. Peginterferon alfa-2a (40 KD) plus ribavirin in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Annals Internal Medicine 2004;140:346-355.
Shiffman ML, Di Bisceglie A, Lindsay KL, Morishima C, Wright EC, Everson G, Lok A, Morgan TR, Bonkovsky H, Lee William, Dienstag J, Ghany M, Everhart J, and the HALT-C study group. Peginterferon alfa-2a for retreatment of patients with chronic HCV who have failed prior treatment with interferon or interferon and ribavirin: results from the lead-in phase of the hepatitis C long-term antiviral treatment against cirrhosis (HALT-C) trial. Gastroenterology 2004;126(4):1015-23.
Bini EJ, Brau N, Curie S, Shen H, Anand BS, Hu K-Q, Jeffers L, Ho SB, Johnson D, Schmidt W, King P, Cheung R, Morgan TR, Awad J, Pedrosa M, Chang K-M, Aytaman A, Simon F, Hagedorn K, Moseley R, Ahmad J, Mendenhall C, Waters B, Strader D, Sasaki A, Rossi S, Wright TL. Epidemiology of hepatitis C and eligibility for antiviral therapy in United States veterans. Am J. Gastroenterology 2005;100(8):1772-9
Morgan TR, Weiss DG, Nemchausky B, Schiff ER, Anand B, Simon F, Kidao J, Bennet C, Mendenhall CL, Nelson D, Lieber CS, Pedrosa M, and the CSP 352 study group. Colchicine treatment of alcoholic cirrhosis: a prospective, randomized, placebo-controlled trial of patient survival. Gastroenterology 2005;128:882-890.
Lok AS, Ghany MG, Goodman Z, Wright EC, Everson GT, Sterling RK, Everhart JE, Di Bisceglie A, Lindsay K, Lee W, Bonkovsky H, Morgan TR, Dienstag J, Morishima C, and the HALT-C Trial Group. Predicting cirrhosis in patients with hepatitis C using standard laboratory tests: results of the HALT-C cohort. Hepatology 2005;42(2):282-92.
Mandayam S, Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. Seminars in Liver Disease 2004;24(3):217-32
Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004;127(5, supplement):S87-S96.
Morgan TR. Clinical usefulness of the Glasgow Alcoholic Hepatitis Score. Nature Clinical Practice Gastroenterology & Hepatology 2006;3(1):4-5 (editorial).
Jamal MM, Saadi Z, Morgan TR. Liver disease in alcohol and hepatitis C. Digestive Diseases 2005;23:285-296.
Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B, Feasibility of identifying HCV genotype 1 patients who respond to 24 weeks of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology 2006;43:954-60.
Morishima C, Morgan TR, Everhart JE Wright EC, Naishadham D, Gretch DR, and HALT-C study group. Utility of a transcription mediated amplification assay for detection of hepatitis C virus RNA during combination therapy in the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology 2006;44:360-367
Shiffman ML, Ghany MG, Morgan TR, Wright EC and HALT-C study group. Dose reduction and sustained virologic response: results from the HALT-C study. Gastroenterology 2007;132:103-12
Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Fried MW, Hadziyannis S, Levy D, Wright TL. Impact of ribavirin dose reductions in HCV genotype 1 patients treated with peginterferon alfa-2a plus ribavirin. Clin Gastroentero Hepatol 2007;5(1):124-9
Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, Shafran SD, Baranger K, Lin A, Soman A, Zeuzem S and the ACCELERATE Investigators (TR Morgan, Member). Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Eng J Med 2007;357:124-34.
Hoefs JC, Morgan TR. 72 weeks of treatment for patients with partial EVR? (editorial). Hepatology 2007;46:1671-4
Di Bisceglie A, Shiffman M, Everson G, Lindsay K, Everhart JE, Wright E, Lee W, Lok A, Bonkovsky H, Morgan TR, Ghany M, Morishima C, Snow K, Dienstag J. Prolonged therapy of advanced hepatitis C with low-dose peginterferon: The hepatitis C long-term treatment against cirrhosis (HALT-C) trial. New England Journal of Medicine (in revision)
Morgan K, Uyuni A, Nandgiri G, Mao L, Casteneda L, Kathirvel E, French SW, Morgan TR. Altered expression of transcription factors controlling lipogenesis during fasting and feeding in an animal model of non-alcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology 2008
Morgan TR, Weiss DG, Nemchausky B, Schiff ER, Anand B, Simon F, Kidao J, Bennet C, Mendenhall CL, Nelson D, Lieber CS, Pedrosa M, and the CSP 352 study group. Colchicine treatment of alcoholic cirrhosis: a prospective, randomized, placebo-controlled trial of patient survival. Gastroenterology 2005;128:882-890.
Lok AS, Ghany MG, Goodman Z, Wright EC, Everson GT, Sterling RK, Everhart JE, Di Bisceglie A, Lindsay K, Lee W, Bonkovsky H, Morgan TR, Dienstag J, Morishima C, and the HALT-C Trial Group. Predicting cirrhosis in patients with hepatitis C using standard laboratory tests: results of the HALT-C cohort. Hepatology 2005;42(2):282-92.
Bardag-Gorce F, Wilson L, Nan L, Li J French, BA, Morgan TR, Morgan K, French SW. CYP2E1 inhibition enhances Mallory body formation. Exp Mol Pathol 2005;78(3):207-11.
Morgan TR. Clinical usefulness of the Glasgow Alcoholic Hepatitis Score. Nature Clinical Practice Gastroenterology & Hepatology 2006;3(1):4-5 (editorial). [PMID: 16397604]
Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B, Feasibility of identifying HCV genotype 1 patients who respond to 24 weeks of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology 2006;43:954-60. PMID: 16628671
Chen S, Morgan TR. Natural history of hepatitis C. Int J Med Sci 2006;3(2):47-52. [PMID: 16614742]
Morishima C, Morgan TR, Everhart JE Wright EC, Naishadham D, Gretch DR, and HALT-C study group. HCV RNA detection by TMA during the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) trial. Hepatology 2006;44:360-367. [PMID: 16871570]
Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, Rogers TE, Banner BF, Shiffman ML, Lindsay KL, Lok ASF, Di Bisceglie AM, Ghany MG, Morishima CM, Everhart JE and the HALT-C study group [TR Morgan, member]. Role of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006;131:1440-51. [PMID: 17196293]
Hu Q-K, Currie SL, Shen H, Cheung RC, Ho SB, Bini EJ, McCracken J, Morgan TR, Brau N, Schmidt WN, Jeffers L, Wright TL for the VA HCV001 Study Group. Clinical implications of hepatic steatosis in patients with hepatitis C: a retrospective analysis of a US multicenter study. Digestive Disease and Sciences 2007;52(2):570-8
Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Gretch DR and HALT-C study group. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007;132:103-12. [PMID: 17241864]
Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Fried MW, Hadziyannis S, Levy D, Wright TL. Impact of ribavirin dose reductions in HCV genotype 1 patients treated with peginterferon alfa-2a plus ribavirin. Clin Gastroentero Hepatol 2007;5(1):124-9. [PMID: 17196435]
Bonkovsky, HL, Snow KK, Malet PF, Black-Madruga C, Fontana RJ, Sterling RK, Kulig CC, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG, Gretch DR, and the HALT-C group. Health-related quality of life in chronic hepatitis C patients with advanced fibrosis. J Hepatology 2007;46(3):420-31. [PMID: 17196293]
Lok AS, Everhart JE, Chung RT, Padmanabhan L, Greeson JK, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Morgan TR, Ghany MG, Morishima C and the HALT-C trial group. Hepatic steatosis is associated with fibrosis and impaired antiviral response in non-diabetics with hepatitis C: analysis of data from the HALT-C clinical trial. Clinical Gastroenterol Hepatol 2007;5(2):245-54. [PMID: 17296533]
Everson GT, Martucci MA, Shiffman ML, Sterling R, Morgan TR, Hoefs JC. Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt. Alimentary Pharmacology and Therapeutics 2007;26(3):401-410. [PMID: 17635375]
Hoefs JC, Morgan TR. 72 weeks of treatment for patients with partial EVR? (editorial). Hepatology 2007;46:1671-4. [PMID: 18046713]
Morgan TR, Lambrecht RW, Bonkovsky HL, Chung RT, Naishadham D, Wright EC, O’Brien TR. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: Results from the HALT-C trial. Journal of Hepatology 2008;49(4):548-556. [PMID: 18619701]
Fried MW, Jensen D, Rodriguez-Torres M, Nyberg L, Di Bisceglie AM, Morgan TR, Pockros P, Lin A, Cupelli L, Duff F, Wang K, Nelson D. Improved outcomes in HCV patients with difficult to treat characteristics: randomized study of higher doses of peginterferon alfa-2a and ribavirin. Hepatology 2008;48:1033-1043. [PMID: 18697207]
Morishima C, Morgan TR, Everhart JE, Wright EC, Chung E, Gretch DR and the HALT-C Trial Group. Interpretation of TMA test results from PCR-negative samples obtained during and after treatment of chronic hepatitis C. Hepatology 2008;48:1412-1419.
Di Bisceglie A, Shiffman M, Everson G, Lindsay K, Everhart JE, Wright E, Lee W, Lok A, Bonkovsky H, Morgan TR, Ghany M, Morishima C, Snow K, Dienstag J. Prolonged therapy of advanced hepatitis C with low-dose peginterferon: The hepatitis C long-term treatment against cirrhosis (HALT-C) trial. New England Journal of Medicine 2008;359:2429-41.
Lok AS, Seeff LB, Morgan TR, Di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD, and the HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009;136:138-148.
Rodriguez-Torres M, Govindarajan S, Diago M, Morgan TR, Anand B, Barange K, Suter F, Lin A, Hooper G, Shiffman M. Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alfa-2a plus ribavirin for 16 or 24 weeks. Liver International 2009;29(2):237-41. [PMID: 18710427]
Butura A, Nilsson K, Morgan K, Morgan TR, French SW, Johansson I, Schuppe-Koistinen I, Ingelman-Sundberg M. Impact of CYP2E1 on development of alcoholic liver disease as studied in a transgenic mouse model. J Hepatol 2009;50(3):572-83. [PMID: 19157621]
Everson GT, Shiffman ML, Morgan TR, Hoefs JC, Sterling RK, Wagner DA, DeSanto J, Curto TM, Wright EC and the HALT-C trial group. Hepatic improvement after sustained virologic response as measured by quantitative tests of liver function: Results from the HALT-C trial. Alimentary Pharmacology and Therapeutics 2009;29(5):589-601 [PMID: 19053983].
Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer R, Wright EC, Hutchinson A, Crenshaw A, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, DiBisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT, O’Brien TR. Variants in interferon alpha pathway genes and response to pegylated-interferon and ribavirin for treatment of chronic HCV infection in the HALT-C trial. Hepatology 2009;49(6):1847-58. [PMID: 19434718]
Lucey M, Mathurin P, Morgan TR. Medical Progress Report: Alcoholic Hepatitis. New England Journal of Medicine 2009;360:2758-69. [PMID: 19553649]
Everhart JE, Lok AS, Kim H-Y, Morgan TR, Lindsay KL, Chung RT, Bonkovsky HL, Ghany MG and the HALT-C trial group. Weight related effects on liver disease progression in the Hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 2009;137:549-57.
Kathirvel E, Morgan K, French SW, Morgan TR. Over-expression of liver-specific CYP2E1 impairs hepatic insulin signaling in a transgenic mouse model of non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2009;21:973-983. [PMID: 19307976]
McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis NM, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS and the IDEAL Study Team [T Morgan, member]. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Eng J Med 2009;361:580-93.
Rodriguez-Torres M, Govindarajan S, Diago S, Morgan TR, Anand B, Barange K, Suter F, Lin A, Hooper G, Shiffman M. Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a plus ribavirin for 16 or 24 weeks. Liver International 2009;29(2):237-41 [PIMD: 18710427]
Ge L, Zhang JG, Samathanum CA, Delgado C, Tarbiyat-Boldaji M, Dan Q, Hoa N, Alipanah R, Nguyen TV, Pham JT, Sanchez R, Wepsic HT, Morgan TR, Jadus M. Cytotoxic T cell immunity against the non-immunogenic, murine, hepatocellular carcinoma Hepa1-6 is directed towards the novel alternative form of macrophage colony stimulating factor. Cellular Immunology 2009;259:117-127
Goodman ZD, Stoddard AM, Bonkovsky HL, Fontana RJ, Ghany MG, Morgan TR, Wright EC and the HALT-C trial group. Fibrosis progression in hepatitis C: morphometric analysis of the HALT-C trial. Hepatology 2009;50(6):1738-49 [PIMD: 19824074]
Lok AS, Everhart JE, Chung RT, Kim H-Y, Everson G, Hoefs J, Greenson JK and the HALT-C trial group [TR Morgan, member]. Evolution of hepatic steatosis in patients with advanced hepatitis C in the HALT-C trial and its impact on progression to cirrhosis. Hepatology 2009;49(6):1828-37 [PIMD: 19291787]
Shiffman ML, Morishima C, Lindsay KL, Hoefs JC, Lee WM, Dienstag JL, Wright EC, Naishadham D, and the HALT-C trial group [TR Morgan, member]. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology 2009;137(6):1986-94 [PIMD: 19747918]
Ghany MC, Lok ASF, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, DiBisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL and the HALT-C trial group. Predicting clinical and histological outcomes based on standard laboratory tests: analysis of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial cohort. Gastroenterology 2010;138(1):136-146 [PIMD: 19766643]
Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, DiBisceglie AM, Morgan TR, Kim H-Y and the HALT-C trial group. Des-gamma-carboxy prothrombin and alpha fetoprotein as biomarkers for hepatocellular carcinoma surveillance: results from the HALT-C trial. Gastroenterology 2010;138:493-502 [PIMD:
Kathirvel E, Chen P, Morgan K, French SW, Morgan TR. Oxidative stress and regulation of antioxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver. Journal of Gastroenterology and Hepatology 2010;25:1136-1143.
Snow KK, Bonkovsky HL, Fontana RJ, Kim H-Y, Sterling R, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG and the HALT-C trial group. Changes in quality of life and sexual health are associated with low dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics 2010;31:719-734
Fontana RJ, Sanyal AJ, Ghany MG, Lee WM, Reid AE, Naishadham D, Everson GT, Kahn JA, DiBisceglie AM, Szabo G, Morgan TR, Everhart JE and the HALT-C trial group. Development and progression of esophageal varices in patients with chronic hepatitis C in a prospective multicenter study. Gastroenterology 2010;138:2321.
Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML, Fontana RJ, DiBisceglie AM, Bonkovsky HL, Dienstag JL and the HALT-C Trial group. Complication rate of percutaneous liver biopsy among persons with advanced chronic liver disease in the HALT-C Trial. Clinical Gastroenterology and Hepatology 2010: [PIMD: 20362695]
Morgan TR, Ghany MG, Kim HY, Snow KS, Shiffman ML, DeSanto JL, Lee WM, DiBisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS. Outcomes of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010:52:833-844 [PIMD: 20564351]
Kathirvel E, Morgan K, Nandgiri G, Sandoval BC, Caudill M, Bottiglieri T, French SW, Morgan TR. Betaine improves non-alcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine. Am J Physiol 2010.
Mathurin P, O’Grady J, Carithers RL, Philipps M, Louvet A, Raymond M-J, Neaveau S, Morgan TR, Maddrey WC, Mendenhall CL. Corticosteroids improve short term survival in patients with severe alcoholic hepatitis: individual data analysis of the last five randomized controlled trials. Gut 2010
Grants
The hepatitis C antiviral, long-term treatment to prevent cirrhosis trial (HALT-C trial)
NIH/NIDDK: Contract N01-DK-9-2320
Principal Investigator
$4,565,924
April 1999 - October 2010
A Phase II, randomized, controlled trial of the safety and efficacy of S-adenosyl-L-methionine disulfate p-toluene sulfonate (SAMe) in reducing serum alpha-fetoprotein (AFP) in patients with hepatitis C cirrhosis and moderately elevated serum AFP
National Cancer Institute, Division of Cancer Prevention. Principal Investigator October 2007 - October 2010. $1.1 million
Link to this profile
https://faculty.uci.edu/profile/?facultyId=3093
https://faculty.uci.edu/profile/?facultyId=3093
Last updated
01/13/2020
01/13/2020